Cart
sales@molnova.com
CDK-IN-10
CAS No. 660822-84-4
CDK-IN-10( —— )
Catalog No. M35483 CAS No. 660822-84-4
CDK-IN-10 is a cell cycle protein-dependent kinase (CDK) inhibitor with potential anticancer activity for cancer research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 193 | In Stock |
|
| 10MG | 276 | In Stock |
|
| 25MG | 430 | In Stock |
|
| 50MG | 581 | In Stock |
|
| 100MG | 768 | In Stock |
|
| 200MG | 1032 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCDK-IN-10
-
NoteResearch use only, not for human use.
-
Brief DescriptionCDK-IN-10 is a cell cycle protein-dependent kinase (CDK) inhibitor with potential anticancer activity for cancer research.
-
DescriptionCDK-IN-10 (example 54) is a cyclin dependent kinase (CDK) inhibitor that can be used in cancer research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number660822-84-4
-
Formula Weight322.36
-
Molecular FormulaC18H18N4O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(NC1=CC=C(C=C1)N2CCOCC2)(=O)C=3C=4C(NN3)=CC=CC4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Valerio Berdini, et al. 1h-indazole-3-carboxamide compounds as cyclin dependent kinases (cdk) inhibitors. WO2004014864
molnova catalog
related products
-
AT-7519
A potent CDK2 inhibitor with IC50 of 47 nM; also inhibits CDK1/4/5 with IC50 of 190/67/18 nM and shows selectivity over some kinases (Aurora A, IR kinase, MEK, PDK1, c-Abl, IC50>10 uM).
-
TG003 B
TG003 is a potent Clk1/Sty inhibitor that inhibits Clk1 and Clk4, inhibits cancer cell growth and induces apoptosis, and can be used in the study of Duchenne muscular dystrophy.
-
AT-7519 hydrochlorid...
A potent CDK2 inhibitor with IC50 of 47 nM; also inhibits CDK1/4/5 with IC50 of 190/67/18 nM and shows selectivity over some kinases (Aurora A, IR kinase, MEK, PDK1, c-Abl, IC50>10 uM).
